Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Original paper

Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population

verfasst von: Mahalakshmi Palani, Sabarinathan Devan, R. Arunkumar, A. J. Vanisree

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Gliomas are the most common primary brain tumors in India. The main epigenetic modification in glioma is aberrant DNA methylation that is now renowned to be a common hallmark of brain tumors. This study was designed to determine the frequency of aberrant CpG island methylation in the promoter regions of p21 and p73 in different grades of glioma and to explore their respective chromosomal aberrations. Total of 160 patients with histologically confirmed grades of glioma (I, II, III, and IV) were included in the study. DNA samples from blood and brain tissues, including benign lesions were subjected to sodium bisulfite conversion and hypermethylation detection using methylation-specific PCR followed by RT–PCR. Western blotting was also carried out for p21 and its related protein, p53. A total of 124 of 160 glioma samples (77.5%) displayed CpG island hypermethylation of both p73, p21 genes associated with the loss of mRNA expression (P < 0.001) and the loss of protein expressions (p53 independent p21 expression). p73 gene showed increased methylation frequency in all grades, 40 of 60 (66%) glioblastomas and 16 of 30 (53.3%) anaplastic astrocytoma, 10 of 20(50%) oligodendrogliomas, 8 of 20 (40%) ependymoma, and low-grade glioma 6 of 20 (30%). The percentage of methylation significantly well correlated with the overall survival and also with chromosomal loss. Thus, the studied glioma patients among south Indians showed a high frequency of aberrant methylation with varied chromosomal signatures in different grades, playing a role in aggressiveness and characterization of a particular grade, the appreciation of which might help for designing a specific therapy.
Literatur
1.
Zurück zum Zitat Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetic joins genetics. Trends Genet. 2000;16:168–74.PubMedCrossRef Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetic joins genetics. Trends Genet. 2000;16:168–74.PubMedCrossRef
2.
Zurück zum Zitat Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed
3.
Zurück zum Zitat Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 2004;10:3441–54.PubMed Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 2004;10:3441–54.PubMed
4.
Zurück zum Zitat Phatak P, Selvi SK, Divya T, Hegde AS, Hegde S, Somasundaram K. Alterations in tumor suppressor gene p53 in human gliomas from Indian patients. J Bio Sci. 2002;27:673–8. Phatak P, Selvi SK, Divya T, Hegde AS, Hegde S, Somasundaram K. Alterations in tumor suppressor gene p53 in human gliomas from Indian patients. J Bio Sci. 2002;27:673–8.
5.
Zurück zum Zitat Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, epidemiology, and end results (SEER) data. J Neurosurg. 1991;88:1–10. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, epidemiology, and end results (SEER) data. J Neurosurg. 1991;88:1–10.
6.
Zurück zum Zitat Lonso ME, Bello MJ, Lomas J, Gonzalez-Gomez P, Arjona D, De Campos JM, et al. Absence of mutation of the p73 gene in astrocytic neoplasms. Int J Oncol. 2001;19:609–12. Lonso ME, Bello MJ, Lomas J, Gonzalez-Gomez P, Arjona D, De Campos JM, et al. Absence of mutation of the p73 gene in astrocytic neoplasms. Int J Oncol. 2001;19:609–12.
7.
Zurück zum Zitat Corn PG, Kuerbitz SJ, Van noesel MM, Esteller M, Compitello N, Baylin SB, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res. 1999;59:3352–6.PubMed Corn PG, Kuerbitz SJ, Van noesel MM, Esteller M, Compitello N, Baylin SB, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res. 1999;59:3352–6.PubMed
8.
Zurück zum Zitat Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998;58:5061–5.PubMed Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998;58:5061–5.PubMed
9.
Zurück zum Zitat Kamiya M, Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. Neuro Oncol. 2002;59:143–9.CrossRef Kamiya M, Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. Neuro Oncol. 2002;59:143–9.CrossRef
10.
Zurück zum Zitat Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System World Health Organization Classification of Tumors. : IARC Press; 2000. Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System World Health Organization Classification of Tumors.  : IARC Press; 2000.
11.
Zurück zum Zitat Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25.PubMed Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25.PubMed
12.
Zurück zum Zitat Rey JA, Bello MJ, Jimenez-Lara A, Vaquero J, Kusak ME, de Campos JM, et al. Loss of heterozygosity for distal markers on 22q in human glioma. Int J Cancer. 1992;51:703–6.PubMedCrossRef Rey JA, Bello MJ, Jimenez-Lara A, Vaquero J, Kusak ME, de Campos JM, et al. Loss of heterozygosity for distal markers on 22q in human glioma. Int J Cancer. 1992;51:703–6.PubMedCrossRef
13.
Zurück zum Zitat Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef
14.
Zurück zum Zitat Banelli B, Casciano I, Romani M. Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene. 2000;19:4553–6.PubMedCrossRef Banelli B, Casciano I, Romani M. Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene. 2000;19:4553–6.PubMedCrossRef
15.
Zurück zum Zitat Staalesen V, Leirvaag B, Lillehaug JR, Lonning PE. Genetic and epigenetic changes in p21 and p21B do not correlate with Resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res. 2004;15:3438–43.CrossRef Staalesen V, Leirvaag B, Lillehaug JR, Lonning PE. Genetic and epigenetic changes in p21 and p21B do not correlate with Resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res. 2004;15:3438–43.CrossRef
16.
Zurück zum Zitat Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer–the application of DNA methylation markers. J Appl Genet. 2006;47:365–75.PubMedCrossRef Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer–the application of DNA methylation markers. J Appl Genet. 2006;47:365–75.PubMedCrossRef
17.
Zurück zum Zitat Esteller M. Cancer epigenetic. DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol. 2003;532:39–49.PubMedCrossRef Esteller M. Cancer epigenetic. DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol. 2003;532:39–49.PubMedCrossRef
18.
Zurück zum Zitat Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed
19.
Zurück zum Zitat Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 2008;27:97–108.CrossRef Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 2008;27:97–108.CrossRef
20.
Zurück zum Zitat Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, et al. Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurgery. 2007;107:398–404.CrossRef Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, et al. Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurgery. 2007;107:398–404.CrossRef
21.
Zurück zum Zitat Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome19 in secondary glioblastomas. J Neuropathol Exp Neurol. 2000;59:539–43.PubMed Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome19 in secondary glioblastomas. J Neuropathol Exp Neurol. 2000;59:539–43.PubMed
22.
Zurück zum Zitat Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Methylation of the p73gene in gliomas. Acta Neuropathol. 2002;104:357–62.PubMed Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Methylation of the p73gene in gliomas. Acta Neuropathol. 2002;104:357–62.PubMed
23.
Zurück zum Zitat Bohnke A, Westphal F, Schmidt A, El-Awady R, Dahm-Daphi J. Role of p53 mutations, protein function and DNA damage for the radio sensitivity of human tumour cells. Int J Radiat Biol. 2004;21:362–409. Bohnke A, Westphal F, Schmidt A, El-Awady R, Dahm-Daphi J. Role of p53 mutations, protein function and DNA damage for the radio sensitivity of human tumour cells. Int J Radiat Biol. 2004;21:362–409.
24.
Zurück zum Zitat Lxohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol. 2000;10:197–202.CrossRef Lxohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol. 2000;10:197–202.CrossRef
25.
Zurück zum Zitat Schwab M, Praml C, Amler L. Genomic instability in 1p and human malignancies. Genes Chromosom Cancer. 1996;16:211–29.PubMedCrossRef Schwab M, Praml C, Amler L. Genomic instability in 1p and human malignancies. Genes Chromosom Cancer. 1996;16:211–29.PubMedCrossRef
26.
Zurück zum Zitat Bello MJ, Leone PE, Nebreda P. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet. 1995;83:160–4.PubMedCrossRef Bello MJ, Leone PE, Nebreda P. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet. 1995;83:160–4.PubMedCrossRef
27.
Zurück zum Zitat Von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59:544–58. Von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59:544–58.
28.
Zurück zum Zitat Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, et al. Methylation profiles of thirty-four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004;4:65.PubMedCrossRef Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, et al. Methylation profiles of thirty-four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004;4:65.PubMedCrossRef
Metadaten
Titel
Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population
verfasst von
Mahalakshmi Palani
Sabarinathan Devan
R. Arunkumar
A. J. Vanisree
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9671-4

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.